Organization (Academic)
Heidelberg University
ClinicalTrials.gov lists Heidelberg University as lead sponsor of 286 trials. It has 15 active development programs and 38 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 8 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 11 in 2026 and about 13 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (5 to 20), forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Logo Logo_University_of_Heidelberg.png : * Logo_unihd.jpg : Uni Heidelberg derivative work: Tou-x ( talk ), via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers Heidelberg University: 286 lead-sponsored trials and 2 legal-entity registrations.
Disease areas (274)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Hypertension, Pulmonary | 19 |
| Hypertension | 18 |
| Diabetes Mellitus | 16 |
| Lung Neoplasms | 13 |
| Malaria | 12 |
Showing 5 of 274 disease areas.
Trials by start year as sponsor or collaborator (30)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 8 |
| 2025 | 12 |
| 2024 | 20 |
| 2023 | 7 |
| 2022 | 13 |
| 2021 | 11 |
| 2020 | 9 |
| 2019 | 16 |
| 2018 | 16 |
| 2017 | 14 |
Showing 10 of 30 years.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (15)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Riociguat Oral Tablet | Hypertension, Pulmonary | Phase 2 | 1 |
| Riociguat Oral Tablet | Scleroderma, Systemic | Phase 2 | 1 |
| Riociguat Oral Tablet | Familial Primary Pulmonary Hypertension | Phase 2 | 1 |
| Obinutuzumab Injection [Gazyva] | Lymphoma | Phase 2 | 1 |
| Riociguat Oral Tablet | Hypertension | Phase 2 | 1 |
Showing 5 of 15 active programs.
Approved assets (38)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| ovaria comp 10 globuli 3 times per day 24 weeks | 1 |
| Esomeprazole 20 mg | 1 |
| lactate and bicarbonate buffered dialysis solutions | 1 |
| Cyclosporine discontinuation | 1 |
| viscum album pini | 1 |
Showing 5 of 38 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 49% hit target (n=47) | 35% on time (n=48) |
Journals published in (383)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| International journal of radiation oncology, biology, physics | 40 |
| BMC cancer | 29 |
| Trials | 21 |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 19 |
| PloS one | 17 |
Showing 5 of 383 journals.
Organization relationships (167)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Helmholtz Association of German Research Centres | Co sponsors trial with | 10 |
| Ludwig-Maximilians-Universität München | Co sponsors trial with | 9 |
| Universitätsmedizin Mannheim | Co sponsors trial with | 6 |
| Rutgers, The State University of New Jersey | Co sponsors trial with | 4 |
| Boston University | Co sponsors trial with | 4 |
Showing 5 of 167 relationships.
Latest dated events (415)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-09 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-07-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-06-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-05-18 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-05 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 415 events.
Biomarker capability evidence (493)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| AARS2 | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar) |
| ABCA4 | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar) |
| ABCC6 | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar) |
| ABCG5 | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar) |
| ABL1 | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 493 evidence rows.
Biomarkers this organization publishes on (877)
Shown in this order: most publications first.
Showing 5 of 877 biomarkers.
On Scientist.com
Heidelberg University is listed as a research supplier in the Scientist.com network.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.
Work with University of Heidelberg Interfacultary Biomedical Faculty on Scientist.com
For prices, more details, or to contact University of Heidelberg Interfacultary Biomedical Faculty, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.